Evidence map›Paper›PMID 40289864›Full record

ArticleNanomedicine (London, England)2025

Wheat germ agglutinin-nanoparticles encapsulating itacitinib target and suppress pro-inflammatory slan+ monocytes.

Karen Alvarez, Cristian A Anacona, Esneyder Ruiz Agudelo, Paula Losada, Víctor H Orozco, Luis Fernando Giraldo, Gloria Vásquez, Daniel Rodriguez, Juan Camilo Díaz, Ricardo Pineda and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Karen AlvarezCellular Immunology and Immunogenetics Group (GICIG), Faculty of Medicine, University of Antioquia, Medellin, Colombia.
Cristian A AnaconaCellular Immunology and Immunogenetics Group (GICIG), Faculty of Medicine, University of Antioquia, Medellin, Colombia.
Esneyder Ruiz AgudeloPolymer Research Laboratory, University of Antioquia, Medellin, Colombia.
Paula LosadaCellular Immunology and Immunogenetics Group (GICIG), Faculty of Medicine, University of Antioquia, Medellin, Colombia.
Víctor H OrozcoPolymer Research Laboratory, University of Antioquia, Medellin, Colombia.
Luis Fernando GiraldoPolymer Research Laboratory, University of Antioquia, Medellin, Colombia.
Gloria VásquezCellular Immunology and Immunogenetics Group (GICIG), Faculty of Medicine, University of Antioquia, Medellin, Colombia.
Daniel RodriguezARTMEDICA Health Service Provider, Medellin, Antioquia, Colombia.
Juan Camilo DíazARTMEDICA Health Service Provider, Medellin, Antioquia, Colombia.
Ricardo PinedaARTMEDICA Health Service Provider, Medellin, Antioquia, Colombia.
Mauricio RojasCellular Immunology and Immunogenetics Group (GICIG), Faculty of Medicine, University of Antioquia, Medellin, Colombia.ORCID 0000-0002-7791-9328

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background6-sulfoLacNAc (slan)+ monocytes, a non-classical monocyte subset, play a pro-inflammatory role in autoimmune diseases like systemic lupus erythematosus (SLE). This study evaluates the therapeutic potential of itacitinib (ITA) encapsulated in wheat germ agglutinin-functionalized nanoparticles (WGA/F127/PNPs) to target and inhibit the JAK-STAT pathway in slan+ monocytes.

methodsWe prepared ITA-loaded WGA/F127/PNPs and analyzed their binding and internalization in various leukocyte subsets using flow cytometry, focusing on slan+ and slan- monocytes. Further, peripheral blood samples from healthy controls (

resultsResults showed that slan+ monocytes from SLE patients were reduced compared to healthy controls (

conclusionITA-loaded WGA/F127/PNPs effectively target and suppress pro-inflammatory slan+ monocytes, presenting a promising, cell-specific therapeutic approach for managing systemic lupus erythematosus and related autoimmune disorders.

Indexed as

Lupus Erythematosus, SystemicMonocytesNanoparticlesPyrimidinesWheat Germ AgglutininsAdultFemaleHLA-DR AntigensHumansMaleMiddle AgedHLA-DR AntigensPyrimidinesWheat Germ Agglutininsjanus kinase inhibitorslupusPLGA nanoparticlesSlan monocyteswheat germ agglutinin

Identifiers

PMID40289864
PMCPMC12068337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.